- Home
- SOGP vs IGC Comparison
SOGP vs IGC Comparison
Compare SOGP & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SOGP
- IGC
- Stock Information
- Founded
- SOGP 2010
- IGC 2005
- Country
- SOGP Singapore
- IGC United States
- Employees
- SOGP N/A
- IGC N/A
- Industry
- SOGP
- IGC Biotechnology: Pharmaceutical Preparations
- Sector
- SOGP
- IGC Health Care
- Exchange
- SOGP NYSE
- IGC Nasdaq
- Market Cap
- SOGP 29.5M
- IGC 33.5M
- IPO Year
- SOGP 2020
- IGC N/A
- Fundamental
- Price
- SOGP $5.14
- IGC $0.37
- Analyst Decision
- SOGP
- IGC Strong Buy
- Analyst Count
- SOGP 0
- IGC 2
- Target Price
- SOGP N/A
- IGC $3.88
- AVG Volume (30 Days)
- SOGP 151.4K
- IGC 7.5M
- Earning Date
- SOGP 08-05-2025
- IGC 08-07-2025
- Dividend Yield
- SOGP N/A
- IGC N/A
- EPS Growth
- SOGP N/A
- IGC N/A
- EPS
- SOGP N/A
- IGC N/A
- Revenue
- SOGP $278,363,908.00
- IGC $1,271,000.00
- Revenue This Year
- SOGP $48.88
- IGC $15.26
- Revenue Next Year
- SOGP N/A
- IGC $3.41
- P/E Ratio
- SOGP N/A
- IGC N/A
- Revenue Growth
- SOGP N/A
- IGC N/A
- 52 Week Low
- SOGP $1.18
- IGC $0.25
- 52 Week High
- SOGP $6.89
- IGC $0.48
- Technical
- Relative Strength Index (RSI)
- SOGP 53.35
- IGC 54.60
- Support Level
- SOGP $5.03
- IGC $0.30
- Resistance Level
- SOGP $5.86
- IGC $0.46
- Average True Range (ATR)
- SOGP 0.85
- IGC 0.04
- MACD
- SOGP -0.19
- IGC 0.00
- Stochastic Oscillator
- SOGP 44.27
- IGC 33.00
About SOGP SOUND GROUP INC SPON ADS EA REP 200 ORD SHS(POST SPLIT)
Sound Group Inc is a world-wide audio-centric social and entertainment company. It Leverages broad product portfolio and in-house technologies, Sound Group caters to user interest in audio entertainment and social networking. Sound Group nurtures a globally diverse and inclusive team, drawing on talent from various countries and regions world-wide.
About IGC IGC Pharma Inc.
IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.